Conventional drug design embraces the “one gene, one drug, one disease” philosophy.
Polypharmacology, which focuses on multi-target drugs, has emerged as a new paradigm in …

In drug discovery, polypharmacology encompasses the use of small molecules with defined
multi‐target activity and in vivo effects resulting from multi‐target engagement. Multi‐target …

The designing of drugs that can simultaneously affect different protein targets is one novel
and promising way to treat complex diseases. Multitarget drugs act on multiple protein …

In the last years, the “one target, one drug” paradigm that has traditionally dominated drug
discovery has been deeply challenged by the evidence that small molecules interact …

Introduction: Over the past couple of years, the cost of drug development has sharply
increased along with the high rate of clinical trial failures. Such increase in expenses is …

Systematic annotation of the primary targets of roughly 1000 known therapeutics reveals that
over 700 of these modulate approximately 85 biological targets. We report the results of …

With the growing understanding of complex diseases, the focus of drug discovery has shifted
away from the well-accepted “one target, one drug” model, to a new “multi-target, multi-drug” …

Multi-target drugs have raised considerable interest in the last decade owing to their
advantages in the treatment of complex diseases and health conditions linked to drug …

Prediction of polypharmacology of known drugs and new molecules against selected
multiple targets is highly useful for finding new therapeutic applications of existing drugs …

Polypharmacology-based strategies are gaining increased attention as a novel approach to
obtaining potentially innovative medicines for multifactorial diseases. However, some within …